Page 46 - Haematologica June

M. Wroblewski et al.
2011;146(6):904-917.
13. Amorim S, Stathis A, Gleeson M, et al.
Bromodomain inhibitor OTX015 in patients with lymphoma or multiple myeloma: a dose-escalation, open-label, pharmacokinetic, phase 1 study. Lancet Haematol. 2016;3(4):e196-204.
14. Berthon C, Raffoux E, Thomas X, et al. Bromodomain inhibitor OTX015 in patients with acute leukaemia: a dose-esca- lation, phase 1 study. Lancet Haematol. 2016;3(4):e186-195.
15. Horne GA, Stewart HJ, Dickson J, et al. Nanog requires BRD4 to maintain murine embryonic stem cell pluripotency and is suppressed by bromodomain inhibitor JQ1 together with Lefty1. Stem Cells Dev. 2015;24(7):879-891.
16. Lee DU, Katavolos P, Palanisamy G, et al. Nonselective inhibition of the epigenetic transcriptional regulator BET induces marked lymphoid and hematopoietic toxi- city in mice. Toxicol Appl Pharmacol. 2016;300:47-54.
17. Bianchi E, Bulgarelli J, Ruberti S, et al. MYB controls erythroid versus megakaryocyte lineage fate decision through the miR-486- 3p-mediated downregulation of MAF. Cell Death Differ. 2015;22(12):1906-1921.
18. Opferman JT, Letai A, Beard C, et al. Development and maintenance of B and T lymphocytes requires antiapoptotic MCL- 1. Nature. 2003;426(6967):671-676.
19. Tripathi P, Koss B, Opferman JT, Hildeman DA. Mcl-1 antagonizes Bax/Bak to pro- mote effector CD4(+) and CD8(+) T-cell responses. Cell Death Differ. 2013; 20(8):998-1007.
20. Ma A, Pena JC, Chang B, et al. Bclx regu- lates the survival of double-positive thymo- cytes. Proc Natl Acad Sci USA. 1995; 92(11):4763-4767.
21. Hu Q, Sader A, Parkman JC, Baldwin TA. Bim-mediated apoptosis is not necessary for thymic negative selection to ubiquitous self-antigens. J Immunol. 2009; 183(12):7761-7767.
22. Carnevalli LS, Scognamiglio R, Cabezas- Wallscheid N, et al. Improved HSC recon- stitution and protection from inflammatory stress and chemotherapy in mice lacking granzyme B. J Exp Med. 2014;211(5):769- 779.
23. Trabucco SE, Gerstein RM, Evens AM, et al. Inhibition of bromodomain proteins for the treatment of human diffuse large B-cell lymphoma. Clin Cancer Res. 2015; 21(1):113-122.
24. Roe JS, Mercan F, Rivera K, Pappin DJ, Vakoc CR. BET Bromodomain Inhibition Suppresses the Function of Hematopoietic Transcription Factors in Acute Myeloid Leukemia. Mol Cell. 2015;58(6):1028-1039.
25. Sandberg ML, Sutton SE, Pletcher MT, et al. c-Myb and p300 regulate hematopoietic stem cell proliferation and differentiation. Dev Cell. 2005;8(2):153-166.
26. Bolden JE, Tasdemir N, Dow LE, et al. Inducible in vivo silencing of Brd4 identifies potential toxicities of sustained BET pro- tein inhibition. Cell Rep. 2014;8(6):1919- 1929.
27. Rahman S, Sowa ME, Ottinger M, et al. The Brd4 extraterminal domain confers transcription activation independent of pTEFb by recruiting multiple proteins,
including NSD3. Mol Cell Biol.
2011;31(13):2641-2652.
28. Hamadani M, Craig M, Awan FT, Devine
SM. How we approach patient evaluation for hematopoietic stem cell transplantation. Bone Marrow Transplant. 2010;45(8):1259- 1268.
29. Ogonek J, Kralj Juric M, Ghimire S, et al. Immune Reconstitution after Allogeneic Hematopoietic Stem Cell Transplantation. Front Immunol. 2016;7:507.
30. Ings SJ, Balsa C, Leverett D, et al. Peripheral blood stem cell yield in 400 normal donors mobilised with granulocyte colony-stimu- lating factor (G-CSF): impact of age, sex, donor weight and type of G-CSF used. Br J Haematol. 2006;134(5):517-525.
31. Anderlini P, Rizzo JD, Nugent ML, et al. Peripheral blood stem cell donation: an analysis from the International Bone Marrow Transplant Registry (IBMTR) and European Group for Blood and Marrow Transplant (EBMT) databases. Bone Marrow Transplant. 2001;27(7):689-692.
32. Anderlini P, Champlin RE. Biologic and molecular effects of granulocyte colony- stimulating factor in healthy individuals: recent findings and current challenges. Blood. 2008;111(4):1767-1772.
33. Anderlini P, Donato M, Chan KW, et al. Allogeneic blood progenitor cell collection in normal donors after mobilization with filgrastim: the M.D. Anderson Cancer Center experience. Transfusion. 1999; 39(6):555-560.
34. Holig K. G-CSF in Healthy Allogeneic Stem Cell Donors. Transfus Med Hemother. 2013;40(4):225-235.
948
haematologica | 2018; 103(6)